BRCA mutations in ovarian and prostate cancer: bench to bedside
Simple Summary DNA damage is one of the hallmarks of cancer. Epithelial ovarian cancer
(EOC)—especially the high-grade serous subtype—harbors a defect in at least one DNA …
(EOC)—especially the high-grade serous subtype—harbors a defect in at least one DNA …
[HTML][HTML] BRCA genes: the role in genome stability, cancer stemness and therapy resistance
I Gorodetska, I Kozeretska, A Dubrovska - Journal of Cancer, 2019 - ncbi.nlm.nih.gov
Carcinogenesis is a multistep process, and tumors frequently harbor multiple mutations
regulating genome integrity, cell division and death. The integrity of cellular genome is …
regulating genome integrity, cell division and death. The integrity of cellular genome is …
Rucaparib in Men With Metastatic Castration-Resistant Prostate Cancer Harboring a BRCA1 or BRCA2 Gene Alteration
PURPOSE BRCA1 or BRCA2 (BRCA) alterations are common in men with metastatic
castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly (ADP …
castration-resistant prostate cancer (mCRPC) and may confer sensitivity to poly (ADP …
EAU-ESTRO-SIOG guidelines on prostate cancer. Part 1: screening, diagnosis, and local treatment with curative intent
N Mottet, J Bellmunt, M Bolla, E Briers… - European urology, 2017 - Elsevier
Objective To present a summary of the 2016 version of the European Association of Urology
(EAU)-European Society for Radiotherapy & Oncology (ESTRO)-International Society of …
(EAU)-European Society for Radiotherapy & Oncology (ESTRO)-International Society of …
Prevalence of germline variants in prostate cancer and implications for current genetic testing guidelines
P Nicolosi, E Ledet, S Yang, S Michalski… - JAMA …, 2019 - jamanetwork.com
Importance Prostate cancer is the third leading cause of cancer-related death in men in the
United States. Although serious, most of these diagnoses are not terminal. Inherited risk for …
United States. Although serious, most of these diagnoses are not terminal. Inherited risk for …
[HTML][HTML] Management of patients with advanced prostate cancer: the report of the Advanced Prostate Cancer Consensus Conference APCCC 2017
Background In advanced prostate cancer (APC), successful drug development as well as
advances in imaging and molecular characterisation have resulted in multiple areas where …
advances in imaging and molecular characterisation have resulted in multiple areas where …
[HTML][HTML] Prostate cancer risks for male BRCA1 and BRCA2 mutation carriers: a prospective cohort study
Background BRCA1 and BRCA2 mutations have been associated with prostate cancer
(PCa) risk but a wide range of risk estimates have been reported that are based on …
(PCa) risk but a wide range of risk estimates have been reported that are based on …
Therapeutic opportunities within the DNA damage response
The DNA damage response (DDR) is essential for maintaining the genomic integrity of the
cell, and its disruption is one of the hallmarks of cancer. Classically, defects in the DDR have …
cell, and its disruption is one of the hallmarks of cancer. Classically, defects in the DDR have …
Genomic markers in prostate cancer decision making
V Cucchiara, MR Cooperberg, M Dall'Era, DW Lin… - European urology, 2018 - Elsevier
Context Although the widespread use of prostate-specific antigen (PSA) has led to an early
detection of prostate cancer (PCa) and a reduction of metastatic disease at diagnosis, PSA …
detection of prostate cancer (PCa) and a reduction of metastatic disease at diagnosis, PSA …
The association between germline BRCA2 variants and sensitivity to platinum‐based chemotherapy among men with metastatic prostate cancer
BACKGROUND Breast cancer 2 (BRCA2)‐associated breast and ovarian cancers are
sensitive to platinum‐based chemotherapy. It is unknown whether BRCA2‐associated …
sensitive to platinum‐based chemotherapy. It is unknown whether BRCA2‐associated …